3 results
Approved WMOCompleted
To assess the local and systemic safety and tolerability of continued ABBV-951 treatment delivered as a CSCI for 24 hours daily.
Approved WMOCompleted
Primary1. To evaluate patient and functional graft survival in stable renal transplant recipients (6-60 months post transplantation) converted from CNI to belatacept-based immunosupression as compared to those continuation of CNI based…
Approved WMOCompleted
To assess the local and systemic safety and tolerability of ABBV-951 delivered as a CSCI for 24 hours daily for up to 52 weeks.